Yanzhi Yang1, Samantha Dodbele1, Thomas Park1, Rainer Glass2, Krishna Bhat3, Erik P Sulman4, Ying Zhang5, Roger Abounader6,7,8. 1. Department of Microbiology, Immunology and Cancer Biology, University of Virginia, PO Box 800168, Charlottesville, VA, 22908, USA. 2. Neurosurgical Research, University Clinics Munich, Munich, Germany. 3. Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. 4. Department of Radiation Oncology, NYU Langone School of Medicine, New York, USA. 5. Department of Microbiology, Immunology and Cancer Biology, University of Virginia, PO Box 800168, Charlottesville, VA, 22908, USA. yz5h@virginia.edu. 6. Department of Microbiology, Immunology and Cancer Biology, University of Virginia, PO Box 800168, Charlottesville, VA, 22908, USA. ra6u@virginia.edu. 7. Department of Neurology, University of Virginia, Charlottesville, VA, USA. ra6u@virginia.edu. 8. Cancer Center, University of Virginia, Charlottesville, VA, USA. ra6u@virginia.edu.
Abstract
BACKGROUND AND PURPOSE: microRNAs are small noncoding RNAs that play important roles in cancer regulation. In this study, we investigated the expression, functional effects and mechanisms of action of microRNA-29a (miR-29a) in glioblastoma (GBM). METHODS: miR-29a expression levels in GBM cells, stem cells (GSCs) and human tumors as well as normal astrocytes and normal brain were measured by quantitative PCR. miR-29a targets were uncovered by target prediction algorithms, and verified by immunoblotting and 3' UTR reporter assays. The effects of miR-29a on cell proliferation, death, migration and invasion were assessed with cell counting, Annexin V-PE/7AAD flow cytometry, scratch assay and transwell assay, respectively. Orthotopic xenografts were used to determine the effects of miR-29a on tumor growth. RESULTS: Mir-29a was downregulated in human GBM specimens, GSCs and GBM cell lines. Exogenous expression of miR-29a inhibited GSC and GBM cell growth and induced apoptosis. miR-29a also inhibited GBM cell migration and invasion. PDGFC and PDGFA were uncovered and validated as direct targets of miR-29a in GBM. miR-29a downregulated PDGFC and PDGFA expressions at the transcriptional and translational levels. PDGFC and PDGFA expressions in GBM tumors, GSCs, and GBM established cell lines were higher than in normal brain and human astrocytes. Mir-29a expression inhibited orthotopic GBM xenograft growth. CONCLUSIONS: miR-29a is a tumor suppressor miRNA in GBM, where it inhibits cancer stem cells and tumor growth by regulating the PDGF pathway.
BACKGROUND AND PURPOSE: microRNAs are small noncoding RNAs that play important roles in cancer regulation. In this study, we investigated the expression, functional effects and mechanisms of action of microRNA-29a (miR-29a) in glioblastoma (GBM). METHODS:miR-29a expression levels in GBM cells, stem cells (GSCs) and humantumors as well as normal astrocytes and normal brain were measured by quantitative PCR. miR-29a targets were uncovered by target prediction algorithms, and verified by immunoblotting and 3' UTR reporter assays. The effects of miR-29a on cell proliferation, death, migration and invasion were assessed with cell counting, Annexin V-PE/7AAD flow cytometry, scratch assay and transwell assay, respectively. Orthotopic xenografts were used to determine the effects of miR-29a on tumor growth. RESULTS:Mir-29a was downregulated in human GBM specimens, GSCs and GBM cell lines. Exogenous expression of miR-29a inhibited GSC and GBM cell growth and induced apoptosis. miR-29a also inhibited GBM cell migration and invasion. PDGFC and PDGFA were uncovered and validated as direct targets of miR-29a in GBM. miR-29a downregulated PDGFC and PDGFA expressions at the transcriptional and translational levels. PDGFC and PDGFA expressions in GBM tumors, GSCs, and GBM established cell lines were higher than in normal brain and human astrocytes. Mir-29a expression inhibited orthotopic GBM xenograft growth. CONCLUSIONS:miR-29a is a tumor suppressor miRNA in GBM, where it inhibits cancer stem cells and tumor growth by regulating the PDGF pathway.
Authors: Shideng Bao; Qiulian Wu; Roger E McLendon; Yueling Hao; Qing Shi; Anita B Hjelmeland; Mark W Dewhirst; Darell D Bigner; Jeremy N Rich Journal: Nature Date: 2006-10-18 Impact factor: 49.962
Authors: Jakub Godlewski; Michal O Nowicki; Agnieszka Bronisz; Gerard Nuovo; Jeff Palatini; Michael De Lay; James Van Brocklyn; Michael C Ostrowski; E Antonio Chiocca; Sean E Lawler Journal: Mol Cell Date: 2010-03-12 Impact factor: 17.970
Authors: Yunqing Li; Fadila Guessous; Ying Zhang; Charles Dipierro; Benjamin Kefas; Elizabeth Johnson; Lukasz Marcinkiewicz; Jinmai Jiang; Yanzhi Yang; Thomas D Schmittgen; Beatriz Lopes; David Schiff; Benjamin Purow; Roger Abounader Journal: Cancer Res Date: 2009-09-22 Impact factor: 12.701
Authors: H J Yeh; I Silos-Santiago; Y X Wang; R J George; W D Snider; T F Deuel Journal: Proc Natl Acad Sci U S A Date: 1993-03-01 Impact factor: 11.205
Authors: Jakub Godlewski; Michal O Nowicki; Agnieszka Bronisz; Shanté Williams; Akihiro Otsuki; Gerard Nuovo; Abhik Raychaudhury; Herbert B Newton; E Antonio Chiocca; Sean Lawler Journal: Cancer Res Date: 2008-11-15 Impact factor: 12.701
Authors: O Martinho; A Longatto-Filho; M B K Lambros; A Martins; C Pinheiro; A Silva; F Pardal; J Amorim; A Mackay; F Milanezi; N Tamber; K Fenwick; A Ashworth; J S Reis-Filho; J M Lopes; R M Reis Journal: Br J Cancer Date: 2009-08-25 Impact factor: 7.640
Authors: Cyntanna C Hawkins; Amber B Jones; Emily R Gordon; Sarah E Williford; Yuvika Harsh; Julia K Ziebro; Catherine J Landis; Sajina Gc; David K Crossman; Sara J Cooper; Sasanka Ramanadham; Ninh Doan; Anita B Hjelmeland Journal: Cells Date: 2022-06-09 Impact factor: 7.666
Authors: Marek Mazurek; Cezary Grochowski; Jakub Litak; Ida Osuchowska; Ryszard Maciejewski; Piotr Kamieniak Journal: Int J Mol Sci Date: 2020-04-27 Impact factor: 5.923